Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-03-23-Speech-1-127"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20090323.16.1-127"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
Mr President, ladies and gentlemen, thank you, Mr Verheugen, for coming and giving us the opportunity to discuss this document together. With regard to the proposal to amend the directive concerning the placing of biocidal products on the market, Parliament has agreed on the need to grant certain extensions to the review period required to correctly assess the main active substances of certain biocidal products, in view of the specific nature of the necessary tests and market requirements. However, you should be aware that we are awaiting the more thorough revision of Directive 98/8/EC on biocidal products to express our views regarding the content. I would therefore like to suggest some ideas for the Commission to think about.
First and foremost, it would be beneficial to make the transition from a directive to a regulation, a legislative instrument that would enable the same provisions to enter into force simultaneously in all Member States, thus regulating the sector uniformly. One key point will be the sharing of data, in accordance with EU guidelines, and, as already implemented with REACH, testing on vertebrates should be avoided or significantly reduced for biocidal products also, thanks to the mandatory sharing of data obtained through such tests among those who register the same active substance, thereby avoiding any duplication of studies.
Data sharing would allow for greater efficiency in the file evaluation system and would cut the cost of drafting these files, which would be significant both for small- and medium-sized enterprises and the national authorities responsible for examining applications.
Emphasis must be placed on simplifying procedures and applying mutual recognition of authorisation for a given product and its use among the different Member States, in order to speed up both procedures and the placing of the biocidal product on the market in the aforesaid States. Following this, the scale of charges and common time periods for examining applications in the different countries should be harmonised, and the authorisation process should be simplified in the case of formulations with minimal differences or variations in colour, for example, thus avoiding extra specific tests requiring further evaluation by each Member State.
Lastly, we must avoid discrimination between European producers of goods treated with biocidal products and extra-Community goods containing such products. I leave it up to the Commission to come up with a solution that the new Parliament, we hope, will be able to support."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples